Lilly Sues US Pharmacies Over Unapproved Compounded Versions of Diabetes Drug Mounjaro

Eli Lilly filed lawsuits against US spas, centers, pharmacies marketing unapproved compounded versions of its diabetes drug Mounjaro.
Lilly states the compounded versions are falsely claiming to contain Mounjaro's active ingredient tirzepatide.
The company says it aims to protect patients as only Lilly's branded Mounjaro is FDA-approved and commercially available.
The FDA previously warned against using compounded versions of similar diabetes drugs like semaglutide.
Lilly states compounded tirzepatide versions can expose users to health risks as they lack FDA review for safety, quality, or efficacy.

cnn.com

Relevant topic timeline:

8/2/2023

Makers of Ozempic and Mounjaro sued over 'stomach paralysis' claims

Main Topic: Lawsuit alleges that Novo Nordisk and Eli Lilly failed to adequately warn patients about the risk of severe stomach problems associated with their diabetes drugs Ozempic and Mounjaro. Key Points: 1. Lawsuit claims that the drugs can cause gastrointestinal injuries, including severe gastroparesis and persistent vomiting. 2. GLP-1 agonists like Ozempic and Mounjaro can slow down food movement through the stomach, leading to feelings of fullness, but can also cause gastrointestinal issues. 3. Over 400 people have come forward claiming gastrointestinal injuries from the drugs, and the lawsuit expects thousands of similar cases.

9/14/2023

Major Companies Sued for False Marketing of Ineffective Phenylephrine in Cold Medicines

Johnson & Johnson, Procter & Gamble, and Walgreens are facing lawsuits alleging that they misled consumers about the effectiveness of cold medicines containing phenylephrine, an ingredient declared ineffective by a unanimous U.S. FDA advisory panel.

9/16/2023

Major Retailers Sued Over Ineffective Decongestant Ingredients

A new lawsuit filed in California targets 14 retailers and pharmaceutical companies, including Walmart, CVS, and Amazon, for selling over-the-counter medicines containing phenylephrine as a decongestant, despite a regulatory panel ruling that it is ineffective, with the plaintiffs seeking class-action status and damages.

10/12/2023

Eli Lilly Soars on Diabetes Drug Success and Promising Obesity Treatment

Shares of pharmaceutical company Eli Lilly are on the rise, driven by the growth potential of its diabetes and obesity products, leading analysts to predict that it could become the first trillion-dollar bio-pharma company. The company's recent approval of Mounjaro for treating type 2 diabetes has resulted in strong revenue growth, and there is anticipation that it will also gain FDA approval for treating obesity. Wall Street analysts are optimistic about Eli Lilly stock, with a consensus rating of Strong Buy.